Creative Planning
KYMR icon

Creative Planning’s Kymera Therapeutics KYMR Stock Holding History

Creative Planning’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Sell
27,009
-1,237
-4% -$106K ﹤0.01% 1755
2026
Q1 		$2.35M Buy
28,246
+14,477
+105% +$1.15M ﹤0.01% 1774
2025
Q4 		$1.07M Buy
13,769
+8,742
+174% +$590K ﹤0.01% 2221
2025
Q3 		$285K Buy
+5,027
New +$227K ﹤0.01% 3186
2025
Q1 		– Sell
-487
Closed -$19.6K – 3610
2024
Q4 		$19.6K Buy
+487
New +$22K ﹤0.01% 3341

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Creative Planning's KYMR Position: Q2 2026 in Review

Creative Planning reduced its Kymera Therapeutics (KYMR) stake by 4.4% in Q2 2026, selling an estimated $106K and leaving 27,009 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1755.

Creative Planning first reported a position in KYMR in Q4 2024 and has held it in 5 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Creative Planning held 27,009 shares of Kymera Therapeutics worth $3.1M as of Q2 2026.
  • Creative Planning sold 1,237 Kymera Therapeutics shares in Q2 2026, an estimated $106K.
  • Kymera Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1755 holding.
  • Creative Planning first reported a position in Kymera Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.